Vir Biotechnology, Inc.

This early-stage trial is testing a new drug called VIR-5818, alone or combined with the immunotherapy pembrolizumab, in people with advanced HER2-expressing cancers that have not responded to standard treatments. The study will first find the safest dose, then expand to see if t…

This Phase 3 trial tests whether a combination of two experimental drugs, tobevibart and elebsiran, can suppress hepatitis D virus in people who are not fully controlled by the current treatment bulevirtide. About 150 adults with chronic hepatitis D will receive the combo as inje…

This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …

This early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…